AstraZeneca will acquire Genxi Biotechnology to deepen the layout of cell therapy in the fields of tumors and autoimmune diseases
阿豆学长长ov
发表于 2023-12-26 19:02:07
251
0
0
On December 26th, AstraZeneca announced that it had signed a final agreement on its acquisition proposal for Genxi Biotechnology. This proposed acquisition will add GC012F CAR-T cell therapy to AstraZeneca's cell therapy pipeline, further deepening its layout in the field of cell therapy.
AstraZeneca introduced that GC012F, based on the FasTCAR technology platform, is an innovative BCMA/CD19 dual target autochimeric antigen receptor T cell therapy (CAR-T) in the clinical stage, which is expected to become a new generation treatment plan for multiple myeloma, other types of malignant hematological tumors, and autoimmune diseases (including systemic lupus erythematosus (SLE)).
It is reported that the principle of autologous CAR-T cell therapy is to re edit and modify the patient's own immune T cells to target pathogenic cells for disease treatment. The production and preparation process is complex and time-consuming. The FasTCAR next-day production technology platform of Genxi Biotechnology can not only significantly shorten production time, but also enhance the health status of T cells, which is expected to improve the effectiveness of autologous CAR-T therapy. This technology is also expected to be applied in the treatment of rare diseases in the future.
AstraZeneca's Global Executive Vice President and Head of Research and Development in the Field of Cancer Therapy, Gao Shucan, stated that the company has established CAR-T and TCR-T pipelines for solid tumors. The acquisition of Genxi Biotechnology will further strengthen AstraZeneca's strength in the field of cell therapy. GC012F will help the company accelerate its strategy of laying out cell therapy in the field of blood tumors, and is expected to provide potential treatment options for blood tumor patients with similar differentiated production.
After the acquisition is completed, Genxi Biotechnology will continue to operate as a wholly-owned subsidiary of AstraZeneca in China and the United States.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Johnson&Johnson CEO: Currently has no intention of producing weight loss drugs and focuses on expanding into fields such as neurology and oncology
- Argentina's economic experiment is about to take place! Today, the global market will witness the impact of "shock therapy"
- Cancer company Aravive's US stock market plummeted by over 57% before trading
- Johnson&Johnson Opsynvi single tablet combination therapy approved by FDA
- 12 weeks of weight loss exceeding 13%. Novo Nordisk's oral therapy has been declared clinically in China
- Baishime Squibb CAR-T therapy approved by the US FDA
- GSK is betting 1.45 billion euros on the imminent outbreak of cross generational business opportunities in mRNA therapy categories?
-
2024年11月7日,由新华社新闻信息中心、新华社上海分社、新华社品牌工作办公室主办的“品牌·让世界更美好”中外品牌论坛在上海举办。此次论坛,理想汽车荣获“通用ESG企业评价规范”年度最佳品牌奖。理想汽车将 ...
- cool88817
- 2 小时前
- 支持
- 反对
- 回复
- 收藏
-
何思文表示,“在进博会这个平台上,我们开启的是倾听模式,通过进博会展出各类产品,收集消费者的需求和反馈,进而帮助决定未来进口到中国的产品。过去,汽车行业的许多创新源于美国加州或欧洲。我相信,中国正 ...
- MaxLucky
- 8 小时前
- 支持
- 反对
- 回复
- 收藏
-
11月5日至10日,第七届中国国际进口博览会(下称“进博会”)在国家会展中心(上海)举办。在进博会期间,平安健康医疗科技有限公司(下称“平安健康”)与美敦力(上海)管理有限公司(下称“美敦力”)达成战 ...
- Hidden2
- 前天 17:06
- 支持
- 反对
- 回复
- 收藏
-
今年上半年业绩表现低迷的百胜中国在第三季度打了个“翻身仗”。11月4日,百胜中国发布三季报显示,今年第三季度,其净利润同比增长22%。而在第一季度、第二季度,该公司净利润增长率分别为-1%、8%,第三季度净 ...
- nihaosifa
- 前天 15:35
- 支持
- 反对
- 回复
- 收藏